This fact sheet describes a phase 3 clinical study that PATH and our partners are conducting in Senegal to evaluate the clinical efficacy of a seasonal, trivalent live attenuated influenza vaccine (LAIV). By providing evidence on how well this type of vaccine works among young children in Senegal, this study will help inform efforts in the scientific community to develop optimal LAIVs for the world’s most vulnerable children, as well as policy decisions for potential future LAIV use in Senegal and other tropical, low-resource countries in Africa.
Corporate author(s): PATH
Publication date: May 2013
120 KB PDF
Also known as: Analyse de l'Efficacité du Vaccin Antigrippal Vivant Atténué au Sénégal
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
Related regions: Africa
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA